|
1
|
Wen PY and Reardon DA: Neuro-oncology in
2015: Progress in glioma diagnosis, classification and treatment.
Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mao K, Lei D, Zhang H and You C:
MicroRNA-485 inhibits malignant biological behaviour of
glioblastoma cells by directly targeting PAK4. Int J Oncol.
51:1521–1532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olar A and Sulman EP: Molecular markers in
low-grade glioma-toward tumor reclassification. Semin Radiat Oncol.
25:155–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Christofides A, Kosmopoulos M and Piperi
C: Pathophysiological mechanisms regulated by cytokines in gliomas.
Cytokine. 71:377–384. 2015. View Article : Google Scholar
|
|
6
|
Strowig T, Henao-Mejia J, Elinav E and
Flavell R: Inflammasomes in health and disease. Nature.
481:278–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lamkanfi M and Dixit VM: Mechanisms and
functions of inflammasomes. Cell. 157:1013–1022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haneklaus M, O'Neill LA and Coll RC:
Modulatory mechanisms controlling the NLRP3 inflammasome in
inflammation: Recent developments. Curr Opin Immunol. 25:40–45.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He Y, Hara H and Núñez G: Mechanism and
regulation of NLRP3 inflammasome activation. Trends Biochem Sci.
41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kent A and Blander JM: Nod-like receptors:
Key molecular switches in the conundrum of cancer. Front Immunol.
5:1852014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Terlizzi M, Casolaro V, Pinto A and
Sorrentino R: Inflammasome: Cancer's friend or foe. Pharmacol Ther.
143:24–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paugh SW, Bonten EJ, Savic D, Ramsey LB,
Thierfelder WE, Gurung P, Malireddi RK, Actis M, Mayasundari A, Min
J, et al: NALP3 inflammasome upregulation and CASP1 cleavage of the
glucocorticoid receptor cause glucocorticoid resistance in leukemia
cells. Nat Genet. 47:607–614. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schneider SL, Ross AL and Grichnik JM: Do
inflammatory pathways drive melanomagenesis. Exp Dermatol.
24:86–90. 2015. View Article : Google Scholar
|
|
14
|
Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai
W, Qiu Y, Li T, Ma X, Liu Y, et al: Estrogen suppresses
hepatocellular carcinoma cells through ERβ-mediated upregulation of
the NLRP3 inflammasome. Lab Invest. 95:804–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma N and Jha S: NLR-regulated pathways
in cancer: Opportunities and obstacles for therapeutic
interventions. Cell Mol Life Sci. 73:1741–1764. 2016. View Article : Google Scholar
|
|
16
|
Wang W, Wang X, Chun J, Vilaysane A, Clark
S, French G, Bracey NA, Trpkov K, Bonni S, Duff HJ, et al:
Inflammasome-independent NLRP3 augments TGF-β signaling in kidney
epithelium. J Immunol. 190:1239–1249. 2013. View Article : Google Scholar
|
|
17
|
Wang H, Wang Y, Du Q, Lu P, Fan H, Lu J
and Hu R: Inflammasome-independent NLRP3 is required for
epithelial-mesenchymal transition in colon cancer cells. Exp Cell
Res. 342:184–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kahlert UD, Nikkhah G and Maciaczyk J:
Epithelial-to-mesenchymal(-like) transition as a relevant molecular
event in malignant gliomas. Cancer Lett. 331:131–138. 2013.
View Article : Google Scholar
|
|
20
|
Ling G, Ji Q, Ye W, Ma D and Wang Y:
Epithelial-mesenchymal transition regulated by p38/MAPK signaling
pathways participates in vasculogenic mimicry formation in SHG44
cells transfected with TGF-β cDNA loaded lentivirus in vitro and in
vivo. Int J Oncol. 49:2387–2398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhuang Y, Peng H, Mastej V and Chen W:
MicroRNA regulation of endothelial junction proteins and clinical
consequence: MicroRNA regulation of endothelial junction proteins
and clinical consequence. Mediators Inflamm. 2016:50786272016.
View Article : Google Scholar
|
|
22
|
Tang M, Zhao Y, Liu N, Chen E, Quan Z, Wu
X and Luo C: Overexpression of HepaCAM inhibits bladder cancer cell
proliferation and viability through the AKT/FoxO pathway. J Cancer
Res Clin Oncol. 143:793–805. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim SY, Menzies AM and Rizos H: Mechanisms
and strategies to overcome resistance to molecularly targeted
therapy for melanoma. Cancer. 123(S11): 2118–2129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X,
Zhao W, Huai W, Guo P and Han L: Deregulation of the NLRP3
inflammasome in hepatic parenchymal cells during liver cancer
progression. Lab Invest. 94:52–62. 2014. View Article : Google Scholar
|
|
25
|
Kong H, Wang Y, Zeng X, Wang Z, Wang H and
Xie W: Differential expression of inflammasomes in lung cancer cell
lines and tissues. Tumour Biol. 36:7501–7513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Li J, Li S, Li Y, Wang X, Liu B, Fu
Q and Ma S: Curcumin attenuates glutamate neurotoxicity in the
hippocampus by suppression of ER stress-associated TXNIP/NLRP3
inflammasome activation in a manner dependent on AMPK. Toxicol Appl
Pharmacol. 286:53–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Allen IC, TeKippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3
inflammasome functions as a negative regulator of tumorigenesis
during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan
X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the
proliferation and migration of A549 lung cancer cells. Oncol Rep.
35:2053–2064. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Munoz L, Yeung YT and Grewal T: Oncogenic
Ras modulates p38 MAPK-mediated inflammatory cytokine production in
glioblastoma cells. Cancer Biol Ther. 17:355–363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fathima Hurmath K, Ramaswamy P and
Nandakumar DN: IL-1β microenvironment promotes proliferation,
migration, and invasion of human glioma cells. Cell Biol Int.
38:1415–1422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun W, Depping R and Jelkmann W:
Interleukin-1β promotes hypoxia-induced apoptosis of glioblastoma
cells by inhibiting hypoxia-inducible factor-1 mediated
adrenomedullin production. Cell Death Dis. 5:e10202014. View Article : Google Scholar
|
|
32
|
Tarassishin L, Lim J, Weatherly DB,
Angeletti RH and Lee SC: Interleukin-1-induced changes in the
glioblastoma secretome suggest its role in tumor progression. J
Proteomics. 99:152–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tarassishin L, Casper D and Lee SC:
Aberrant expression of interleukin-1β and inflammasome activation
in human malignant gliomas. PLoS One. 9:e1034322014. View Article : Google Scholar
|
|
34
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song H, Zhang Y, Liu N, Zhao S, Kong Y and
Yuan L: miR-92a-3p exerts various effects in glioma and glioma
stem-like cells specifically targeting CDH1/β-catenin and
Notch-1/Akt signaling pathways. Int J Mol Sci. 17:E17992016.
View Article : Google Scholar
|
|
36
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI
|
|
37
|
Mueller S, Phillips J, Onar-Thomas A,
Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD,
Weiss WA, et al: PTEN promoter methylation and activation of the
PI3K/Akt/mTOR pathway in pediatric gliomas and influence on
clinical outcome. Neuro-oncol. 14:1146–1152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moon SH, Kim DK, Cha Y, Jeon I, Song J and
Park KS: PI3K/Akt and Stat3 signaling regulated by PTEN control of
the cancer stem cell population, proliferation and senescence in a
glioblastoma cell line. Int J Oncol. 42:921–928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang F, Wang Y, Sun P, Wang ZQ, Wang DS,
Zhang DS, Wang FH, Fu JH, Xu RH and Li YH: Fibrinogen promotes
malignant biological tumor behavior involving
epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in
esophageal squamous cell carcinoma. J Cancer Res Clin Oncol.
143:2413–2424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mizushina Y, Shirasuna K, Usui F, Karasawa
T, Kawashima A, Kimura H, Kobayashi M, Komada T, Inoue Y, Mato N,
et al: NLRP3 protein deficiency exacerbates hyperoxia-induced
lethality through Stat3 protein signaling independent of
interleukin-1β. J Biol Chem. 290:5065–5077. 2015. View Article : Google Scholar
|
|
41
|
Morris EJ, Kawamura E, Gillespie JA, Balgi
A, Kannan N, Muller WJ, Roberge M and Dedhar S: Stat3 regulates
centrosome clustering in cancer cells via Stathmin/PLK1. Nat
Commun. 8:152892017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao YY, Yu J, Liu TT, Yang KX, Yang LY,
Chen Q, Shi F, Hao JJ, Cai Y, Wang MR, et al: Plumbagin inhibits
the proliferation and survival of esophageal cancer cells by
blocking STAT3-PLK1-AKT signaling. Cell Death Dis. 9:172018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saitoh M, Endo K, Furuya S, Minami M,
Fukasawa A, Imamura T and Miyazawa K: STAT3 integrates cooperative
Ras and TGF-β signals that induce Snail expression. Oncogene.
35:1049–1057. 2016. View Article : Google Scholar
|
|
44
|
Lech M, Lorenz G, Kulkarni OP, Grosser MO,
Stigrot N, Darisipudi MN, Günthner R, Wintergerst MW, Anz D,
Susanti HE, et al: NLRP3 and ASC suppress lupus-like autoimmunity
by driving the immunosuppressive effects of TGF-β receptor
signalling. Ann Rheum Dis. 74:2224–2235. 2015. View Article : Google Scholar
|
|
45
|
Xiong S, Cheng JC, Klausen C, Zhao J and
Leung PC: TGF-β1 stimulates migration of type II endometrial cancer
cells by downregulating PTEN via activation of SMAD and ERK1/2
signaling pathways. Oncotarget. 7:61262–61272. 2016.PubMed/NCBI
|
|
46
|
Eritja N, Felip I, Dosil MA, Vigezzi L,
Mirantes C, Yeramian A, Navaridas R, Santacana M, Llobet-Navas D,
Yoshimura A, et al: Smad3-PTEN regulatory loop controls
proliferation and apoptotic responses to TGF-beta in mouse
endometrium. Cell Death Differ. 24:1443–1458. 2017. View Article : Google Scholar : PubMed/NCBI
|
